Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech, Inc. announced the results of its 2025 third extraordinary general meeting, where key resolutions regarding the re-appointment of board members and executives were approved. The re-appointments include the chairman of the board, chairman of the board of supervisors, and the chief executive officer, which are expected to provide continuity in leadership and strategic direction for the company.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of monoclonal antibody biosimilar and innovative biologics. The company operates in the pharmaceutical industry, aiming to provide affordable and accessible healthcare solutions.
Average Trading Volume: 1,440,370
Technical Sentiment Signal: Buy
Current Market Cap: HK$40.22B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.